Concepedia

Phase III Trial of Capecitabine Plus Oxaliplatin As Adjuvant Therapy for Stage III Colon Cancer: A Planned Safety Analysis in 1,864 Patients

Hans‐Joachim Schmoll, Thomas H. Cartwright, Josep Tabernero, Marek P. Nowacki, Arié Figer, Jean A. Maroun, Timothy Price, Robert Lim, Eric Van Cutsem, Young-Suk Park,

Journal of Clinical Oncology · 2006 · 296 citations · 19 references

DOI

Abstract

XELOX has a manageable tolerability profile in the adjuvant setting. Efficacy data will be available within the next 24 months.

References

19

Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer

Thierry André, C. Boni, Lamia Mounedji-Boudiaf et al. · New England Journal of Medicine · 2004 · 3.6K citations · Full text

Capecitabine as Adjuvant Treatment for Stage III Colon Cancer

Chris Twelves, A. Wong, Marek P. Nowacki et al. · New England Journal of Medicine · 2005 · 1.2K citations · Full text

Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer.

M. J. OʼConnell, J A Mailliard, Michael Kahn et al. · Journal of Clinical Oncology · 1997 · 585 citations

XELOX (Capecitabine Plus Oxaliplatin): Active First-Line Therapy for Patients With Metastatic Colorectal Cancer

Jim Cassidy, Josep Tabernero, Chris Twelves et al. · Journal of Clinical Oncology · 2004 · 522 citations · Full text

First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous5-fluorouracil/leucovorin

Jim Cassidy, Chris Twelves, Eric Van Cutsem et al. · Annals of Oncology · 2002 · 521 citations

, , +6